Sugi Predict

Sugi Predict / Compounds / SCHEMBL2370008

SCHEMBL2370008

SCHEMBL2370008

CC1(C)OB(c2cc(F)nc(F)c2)OC1(C)C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 13/20 0.48
▸ LIPG Q9Y5X9 13/20 0.48
▸ FFAR1 O14842 1/20 0.36
▸ IDO1 P14902 1/20 0.35
▸ TDO2 P48775 1/20 0.35
▸ CA1 P00915 2/20 0.35
▸ CA2 P00918 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA3 P07451 1/20 0.35
▸ CA4 P22748 1/20 0.35
▸ CA6 P23280 1/20 0.35
▸ CA5A P35218 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ CA5B Q9Y2D0 1/20 0.35
▸ SNCA P37840 1/20 0.35
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ F11 P03951 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16534924 0.89 LPL (0.43) LPLLIPGFFAR1IDO1TDO2
SCHEMBL29573905 0.89 LPL (0.43) LPLLIPGFFAR1IDO1TDO2
SCHEMBL3028464 0.87 LPL (0.42) LPLLIPGFFAR1IDO1TDO2
SCHEMBL31734467 0.87 LPL (0.42) LPLLIPGFFAR1IDO1TDO2
SCHEMBL30541765 0.87 LPL (0.42) LPLLIPGFFAR1IDO1TDO2
SCHEMBL22324125 0.86 LPL (0.41) LPLLIPGFFAR1IDO1TDO2
SCHEMBL1674073 0.84 LPL (0.40) LPLLIPGFFAR1IDO1TDO2
SCHEMBL517499 0.79 LPL (0.52) LPLLIPGFFAR1CA1CA2
SCHEMBL29109004 0.79 LPL (0.44) LPLLIPGFFAR1CA1CA2
SCHEMBL9948194 0.78 LPL (0.57) LPLLIPGFFAR1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
EP-4724440-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 — — EP disclosed
US-12479835-B2 Process for preparing 1-([3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide INTERVET INC. (US) 2025-11-25 — — US disclosed
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
US-20250236609-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-07-24 — — US disclosed
US-20250206729-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-06-26 — — US disclosed
WO-2025137105-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2025-06-26 — — WO disclosed
WO-2025129019-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2025-06-19 — — WO disclosed
EP-3077401-A1 SERINE/THREONINE KINASE INHIBITORS Genentech, Inc. (US) 2016-10-12 — — EP disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
US-20150182537-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-07-02 — — US disclosed
US-20150182537-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-07-02 — — US disclosed
US-20150182537-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-07-02 — — US disclosed
WO-2015085007-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-06-11 — — WO disclosed
WO-2015085007-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-06-11 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2011110575-A1 DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2011-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206729-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF BRAF, MAP2K2, MAP2K1 LPL 4799/4885LIPG 3922/4885FFAR1 4772/4885
US-12479835-B2 Process for preparing 1-([3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide CYP4B1, CYP3A4, CYP4F3 LPL 4333/4885LIPG 4733/4885FFAR1 1173/4885
US-20250236609-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF VPS35, VPS28, VPS26B LPL 2330/4885LIPG 338/4885FFAR1 3701/4885
US-20150182537-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 LPL 4345/4885LIPG 2654/4885FFAR1 3879/4885
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, CCR1, CXCR2 LPL 701/4885LIPG 511/4885FFAR1 415/4885
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS RIPK2, RIPK1, RIPK4 LPL 3936/4885LIPG 2771/4885FFAR1 1953/4885
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS LPL 2876/4885LIPG 1025/4885FFAR1 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.